Merck KGaA's (MKGAF.PK) Erbitux treatment helped patients with metastatic colon cancer live...


Merck KGaA's (MKGAF.PK) Erbitux treatment helped patients with metastatic colon cancer live around four months longer than Roche's Avastin in a head-to-head study. However, the overall response rate, as measured by tumor shrinkage, was the about same, as was the amount of time it took for the disease to worsen. A larger trial of the drugs is due to take place next year. Merck's U.S. partners in Erbitux are Eli Lilly (LLY) and Bristol-Myers Squibb (BMY). The findings were presented at the annual meeting of American Society of Clinical Oncology.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs